Low- and Middle-Income Countries (LMICs) face significant inequity in terms of access to vaccines and other biologics and are making efforts to establish biological manufacturing in their regions. Establishing such manufacturing capacity, through bilateral technology transfer or through local R&D efforts is often hindered by the lack of a trained workforce in biomanufacturing.
To address this gap and to build the biomanufacturing capacity in LMICs, the World Health Organization (WHO) and the Ministry of Health and Welfare of the Republic of Korea (MoHWK) established the Global Training Hub for Biomanufacturing (GTH-B).
The hub is mandated to provide training in manufacturing of high-quality vaccines and biologics in an industrial setting to resolve inequality in access to vaccines and biologics worldwide by expanding manufacturing capacity in LMICs.
Since 2022, the GTH-B has run, through the International Vaccine Institute (IVI), two editions of the ‘Introductory Course for Biologics Development and Manufacturing’, and ‘Introductory Course for Standard Practice (GxP)’ to provide GTH-B training to about 500 people in more than 40 LMICs.
For the third year, the Republic of Korea in agreement with WHO is organizing a new training operated by IVI focusing on introduction to biologics development and manufacturing in June 2024 for 130 trainees from LMICs.
To learn more about this course and submit your application, please visit this web page .